Name of Classification Dosage/Route/ Mechanism Indication Contraindication Adverse effect Nursing intervention

Drug Frequency/ of action

(Telmisartan) Cardiovascular 40 mg. Blocks the Treatment of  Presence of Headache, Assessment:

Drugs p.o. vasoconstricti hypertension hematopoietic rash, pruritus,
Micardis OD ve and disorders nausea,
Angiotensin II aldosterone- fullness,
 Assess patient’s
 History of
Antagonists secreting thrombotic dyspepsia, GI condition before therapy.
effects of thrombocytop pain,  Assess for heart failure.
angiotensin II enic purpura flatulence,  Obtain baseline and liver
by selectively (TTP) anorexia. status before therapy.
blocking the  Presence of Prolonged
binding of hemostatic bleeding time,
angiotensin II bleeding
Implementation:
disorder or
to angiotensin active complications.
I receptor in pathologic Weakness,  Instruct patient to
many tissues. bleeding pain. comply with dosage schedule
 Severe liver even if feeling better.
impairment  Tell patient that drug
may cause light-headedness,
dizziness and fainting.
 Instruct
 patient with heart failure to
report decreased urine output.
 Teach patient the
importance of diet control.
 Name of Classification Dosage/Route/ Mechanism Indication Contraindication Adverse effect Nursing intervention
Drug Frequency/ of action

(Ferrous Dietary/Nutrition 1 tab Provides/Repl Prevention Hypersensitivity to GI irritation, Assessment:

Sulfate) al Preparations p.o. aces and any ingredient, anorexia,
AM- TID p.c. elemental treatment of hemosiderosis, diarrhea,
Hematinics iron, an iron- hemolytic anemia. constipation,
 Obtain baseline
Europharma
Ferrous essential deficiency dark stool. assessment of iron deficiency.
Sulfate, component in anemia. Teeth staining  Monitor for adverse
Anemicon, formation of with liquid reaction: GI: nausea, epigastric
Brofesol, hemoglobin in formulation. pain, constipation, diarrhea,
Feosol red blood cell black stool, anorexia.
spansule, development.
 Assess diet and
Ferglobin,
Fer-In-Sol, nutrition.
Rhea
Ferrous Implementation:
Sulfate
 Instruct patient not to
substitute one iron salt for
another because they have
different elemental iron
content.
 Instruct patient to
swallow the whole tablet and
not to double the dose if
missed.
Name of Classification Dosage/Route/ Mechanism Indication Contraindication Adverse effect Nursing intervention
Drug Frequency/ of action

(EPO) Hematopoietic 4000 I.U. Mimics effects Management Hypersensitivity to Hypertension; Assessment:
Growth Factors of of anemia mammalian cell- tachycardia;
Eprex Subcutaneous erythropoietin associated derived products clotted
Injection which with chronic or human vascular
 Monitor renal and blood
functions as a renal failure albumin, access. studies.
2x a week growth factor in dialysis uncontrolled Headache;  Assess for CNS
(Wednesday and as a and hypertension. seizures. symptom: coldness, sweating,
and Saturday) differentiating predialysis Nausea; pain in long bones.
factor, patients; they vomiting;  Monitor B/P
enhancing may reduce diarrhea.
RBC or obviate Shortness of
production; the need for breath. Implementation:
drug is blood Allergy,
developed by transfusions including  Advise patients to take
recombinant in these anaphylaxis, iron supplements, Vit. B12, and
DNA patients. skin rashes folic acid as directed.
technology. Also used in and urticaria;
the fever;  Instruct patient to report
management paresthesia; signs or symptoms of edema.
of arthralgia.
chemotherap
y-induced
anemia in
patients with
non-myeloid
malignant
disease.
 Name of Classification Dosage/Route/ Mechanism Indication Contraindication Adverse effect Nursing intervention
Drug Frequency/ of action

(Domperidone) Antiemetic/ 1 tab Selectively Anti-emetic Should not be The incidence Assessment:
Antivertigo blocks for the short- used when of central
Motilium p.o. peripheral term stimulation of effects such
dopamine treatment of muscular as
 Assess for GI complaints.
TID receptors in nausea and contractions might extrapyramida  Assess for pain.
the GI wall vomiting of adversely affect l reactions or  Assess for change in
and in the various GI conditions as drowsiness bowel habits.
chemorecepto etiologies, in GI hemorrhage, may be lower
r-tor trigger including that obstruction. than Implementation:
zone (CTZ) associated Perforation, or metocloprami
thus with cancer immediately after de.
enhancing therapy, and surgery.  Inform the patient to
normal nausea and take the medication before
synchronized vomiting meals.
GI peristalsis associated  Instruct the patient to
and motility in with inform the physician if
the proximal levodopa or
region of the bromocriptin transient intestinal cramps,
GIT; e therapy for increased plasma prolactin
counteract parkinsonism levels and extrapyramidal
anti- . Also used symptoms occur.
cholinergic- for its
induced prokinetic
relaxation of actions in
the lower disorders of
esophageal gastrointestin
sphincter. al motility.
Name of Classification Dosage/Route/ Mechanism Indication Contraindication Adverse effect Nursing intervention
Drug Frequency/ of action

(Calcium Vitamins and 1 tab Decreases Antacid, Hypercalcemia Constipation, Assessment:

carbonate) Minerals total acid load calcium flatulence,
p.o. of GI tract. supplement, diarrhea,
Increases hyperphosph gastric
 Assess for adverse
Calci-Aid,
calcium q 6 hrs. esophageal atemia, hypersecretio reactions: constipation, gastric
Sandoz sphincter osteoporosis. n. distention, flatulence and
chewable tone, rebound hyperacidity.
tablet, strengthens  Assess for nausea and
Calsan gastric vomiting.
mucosal
barrier and
reduce pepsin Implementation:
activity by
elevating  Advise patient to take as
gastric pH. directed.
 Advise patient to
increase fluids to 2 l, unless
contraindicated, to add bulk to
diet for constipation.
 Tell patient to notify
physician of persistent
symptoms like tarry stools or
coffee ground vomitus.
Name of Classification Dosage/Route/ Mechanism Indication Contraindication Adverse effect Nursing intervention
Drug Frequency/ of action

(Insulin) Anti-diabetic 160-200 4 “u” Decreases Management Hypoglycemia, Lipodystrophy, Assessment:

drugs 201-240 6 “u” blood of type 1 DM insulinoma, insulin resistance,
Humulin R 241-280 8 “u” glucose; by or insulin hypersensitivity redness, pain,
Short-acting >282 10 “u” transport of dependent reactions,IV itching, hives,
 Monitor fasting blood
insulin glucose into DM (IDDM) administration of swelling or glucose, 2 hrs. after meals.
Subcutaneous cells and the and type 2 insulin inflammation.  Monitor body weight
conversion of DM or non- suspension, Hypoglycemia, periodically.
glucose to insulin- diabetic coma. temporary visual  Assess for hypoglycemic
glycogen dependent impairment. reactions that can occur during
indirectly DM
increases (NIDDM)whic
peak time.
blood h cannot be  Observe injection sites
pyruvate and controlled by for signs and symptoms of local
lactate, diet, exercise hypersensitivity such as
decreases or weight redness, itching, or burning.
phosphate reduction  Assess for
and alone.
potassium. hyperglycemia: acetone breath,
polyuria, fatigue, polydipsia,
flushed, dry skin, lethargy.

Implementation:

 Instruct patient on
proper technique for
administration.
 Tell patient not to stop
insulin therapy without
medical approval.
 Drug Study

Realino, Sheryl G. C.I. Ms. Bautista

IV – 2 2-10 p.m.
Grp. 8